Market Research Future

Dysmenorrhea Treatment Industry Trends and Global Major Key Players Research Report Foresight to 2027


Pune, India -- (SBWIRE) -- 07/24/2017 -- Market Growth Influencer

Rising prevalence of dysmenorrhea, high consciousness level and growing concern about dysmenorrhea among females, contribution of companies for developing advanced treatments, and government campaigns with respect to women healthcare are effectively sanctioning the growth of dysmenorrhea treatment market.

However, consequence and complications of long term treatment, extensive morbidity of dysmenorrhea which leads to inadequate treatment, and traditional values of families would hinder the growth of dysmenorrhea treatment market.

Market Segments

The Global Dysmenorrhea Treatment Market can be segmented on the basis of types, treatment, and applications.

Global Dysmenorrhea Treatment Market by Types:

- Primary
- Secondary

Global Dysmenorrhea Treatment Market by Treatment methods:

- General Diagnosis
- Non-hormonal medical treatment
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Over-the-counter (OTC) medications

Hormonal medical treatment

- Combined oral contraceptive
- Progestin regimens
- Levonorgestrel intrauterine system (LN-IUS)
- Surgical Treatment

Global Dysmenorrhea Treatment Market by Applications:

- Pharmaceuticals
- Hospitals
- Clinics

Request a Sample Report @

Market Overview

Globally, more than 50% of post pubescent menstruating women are affected by dysmenorrhea, with 10–12% of them having severe dysmenorrhea with incapacitation for 1–3 days each month. Because young women constitute a significant percentage of the adult work force in the US, nearby 600 million working hours or 2 billion dollars are lost annually because of incapacitating dysmenorrhea if adequate relief is not provided. Women who continue to work or to attend classes have been shown to have lower work output or scores during their dysmenorrhea.

Dysmenorrhea is characterized as recurrent pelvic pain associated with menstruation. Dysmenorrhea is the most well-known gynecologic dissension in adolescents, happening in 60-93% of ladies in this demographic congregation. It is more predominant amid late youthfulness, with the start of ovulatory cycles a few years after the beginning of menstruation. Crest occurrence happens amid the late adolescent years and mid-20s.

It is for the most part ordered into two general classes:

- Primary Dysmenorrhea alludes: to menstrual pain without any fundamental pelvic pathology.

- Secondary Dysmenorrhea alludes: to menstrual pain connected with a predefined organic etiology.

- Symptoms of Dysmenorrhea include cramping pain in the midline in the suprapubic area, and may have associated backache, leg pains, nausea, vomiting, light-headedness and headache.

Market Application
The Dysmenorrhea is been treated by various methods such as with the help of medicines, with the help of high level treatment and in some severe cases surgeries is been preferred. Presently Transcutaneous electrical nerve stimulation (TENS) device is been used for the treatment of Dysmenorrhea.

Browse Report Details @

Key Players:
Some of the major players of Global Dysmenorrhea Treatment Market are as follows:

- Novartis Pharmaceuticals Corporation
- Merck, Inc.
- Bayer Schering Pharma AG
- Vanita Therapeutics
- Alvogen
- Pfizer, Inc.
- Roche Laboratories
- Taj Pharmaceuticals, Ltd.
- Sanofi
- Terramedic, Inc.

Latest Trends in Dysmenorrhea Treatment Market:

- Novartis receives three FDA Breakthrough Therapy Designations in 2016 for Ilaris to treat rare types of Periodic Fever Syndromes.

- Transcutaneous electrical nerve stimulation (TENS) is an established method for pain relief in Dysmenorrhea, which does not involve the use of medication.

Regional Analysis of Dysmenorrhea Treatment Market:
The regional analysis includes North America, Europe, Asia Pacific, Middle East and rest of the world.

The Global Dysmenorrhea Treatment Market is expected to grow with a CAGR of more than 3% during the forecasted period due to high usage of low price OTC (over-the-counter) and off-label treatment.

North America:
The North America is dominating the Dysmenorrhea market followed by Europe due the existence of a large number of Dysmenorrhea patients in these regions. North America and European Dysmenorrhea market is driven by high healthcare spending, improved healthcare infrastructure and high awareness about the disease and high availability of its treatments.

Asia-Pacific is expected to have rapid growth in Dysmenorrhea market due to increase in purchasing power, changing healthcare infrastructure and increased awareness for clinical facilities in the regions such as India, China, Japan and others. Support of government and non-profit organizations in awareness campaigns is enhancing the Dysmenorrhea market by creating awareness about the disease, its symptoms and various treatments available, in the mind of the consumers.

Request Table of Contents for this Report @